EW | Ticker Profile - Titan Protect

Edwards Lifesciences

Health Care · Health Care Equipment · US

$85.96

Data: 2026-05-15

✓ ETHICAL PASS

MODERATE MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$46.7B

Total market value of the company

Trailing P/E

43.88

Expensive — high growth expected

Forward P/E

24.13

Based on estimated future earnings — lower means cheaper

Rev Growth

+16.7%

Year-over-year revenue change

Profit Margin

17.4%

How much profit the company keeps from each dollar of revenue

ROE

10.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$97.15

+13% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 27 analysts covering this stock

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

https://www.edwards.com

Country: United States Employees: 16,000 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

5.1% PASS

Debt must be below 33% of total assets

Cash Ratio

1.8% PASS

Interest-bearing cash below 33% of assets

Receivables

26.3% PASS

Receivables below 49% of assets

Revenue Purity

2.8% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$56.17

What our model estimates this business is worth per share

Margin of Safety

-53.0%

Trading above fair value — no margin of safety

Rating

OVERVALUED

Overall assessment combining ethics, valuation, and quality

Percentile

90.3th

Ranks in the top 10% of our 13,571 screened universe

Ethical Score

83.9

Valuation Score

44.5

Quality Score

65.3

Combined

64.2

Trading at $81, 45% above fair value of $56. Moderate competitive position. Passes all ethical screens. Ranks better than 58% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.196

Positive but modest risk-adjusted returns

Kelly Fraction

0.0149

Marginal edge — very small allocation suggested

Calmar Ratio

0.008

Drawdown risk outweighs the returns — higher risk profile

Annual Return

0.3%

Historical annualised return based on price data

Max Drawdown

-36.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

439

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.87

Less volatile than the market — more defensive

52W High

$87.89

2% below the year high

52W Low

$72.30

19% above the year low

Avg Volume

4,949,043

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.1%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.85

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.07

Conservative use of debt — low financial risk

Current Ratio

4.42

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.30

Like current ratio but excludes inventory — stricter test

Gross Margin

77.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

31.2%

Profit from core operations before interest and tax

Free Cash Flow

$902M

Positive — the business generates more cash than it spends

Revenue (TTM)

$6.3B

Total revenue over the last 12 months

Net Income

$1.1B

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$110.00

Target Median

$97.15

Target Low

$84.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-05-18	LIPPIS DANIEL J	Officer	620	$45,062
2026-05-18	LIPPIS DANIEL J	Officer	620	$50,307
2026-05-15	BOBO DONALD E JR	Officer	17,968	$1,472,678
2026-05-12	ZOVIGHIAN BERNARD J	Chief Executive Officer	26,640	—
2026-05-12	ZOVIGHIAN BERNARD J	Chief Executive Officer	36,351	$2,833,013
2026-05-11	CHOPRA DAVEEN	Officer	13,583	—
2026-05-11	BOBO DONALD E JR	Officer	13,457	—
2026-05-11	ZOVIGHIAN BERNARD J	Chief Executive Officer	47,207	—
2026-05-11	ULLEM SCOTT B	Chief Financial Officer	19,830	—
2026-05-11	ZOVIGHIAN BERNARD J	Chief Executive Officer	9,711	—

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go